Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Psychiatry Other
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Psychiatry Other
    FDA Approves Quetiapine Fumarate for the Treatment of Bipolar Depression, Mania - (DGNews)
    Bipolar Disorder in Children Appears Likely to Continue Into Young Adulthood - (DGNews)
    A 60-year-old woman with mild memory impairment: review of mild cognitive impairment - (JAMA)
    Longer-Duration Psychotherapy Appears More Beneficial for Treatment of Complex Mental Disorders - (DGNews)
    Behavioural Modification Programs Help Obese Children Manage Their Weight - (DGNews)

    News archive

     Recent webcasts/CME - Psychiatry Other
    • Differentiating Between Schizophrenia and Bipolar Disorder: A Closer Look at Overlapping Symptoms
    • 22-Year-Old Man With Dysfunctional Social- and Work-Related Behavior
    • 29-Year-Old Woman With Agitation and Paranoia
    • Advances in Alzheimer's Disease and Vascular Dementia: Benchmarks in Diagnosis and Treatment
    • Neurological, Psychological or Psychiatric Dysfunction in Patients with SLE

      Webcasts/CME archive

       Recent cases - Psychiatry Other
        Lithium Intoxication Related Multiple Temporary ECG Changes : A Case Report
        Factitious Lymphoedema as a Psychiatric Condition Mimicking Reflex Sympathetic Dystrophy: A Case Report
        Topiramate-Induced Psychosis in Two Members of the One Family: A Case Report
        Childhood Autism in a 13 Year Old Boy with Oculocutaneous Albinism: A Case Report
        Unexpected Depletion in Plasma Choline and Phosphatidylcholine Concentrations in a Pregnant Woman with Bipolar Affective Disorder Being Treated with Lithuim, Haloperidol and Benztropine: A Case Report

        Cases archive
          




        my personal edition > psychiatry other > news
        divider

          E-Mail this DGDispatch to a colleague

        DGDispatch


        Olanzapine Plus Lithium or Valproate Effective for Bipolar Relapse Prevention: Presented at APA

        By Bruce Sylvester

        PHILADELPHIA, PA -- May 22, 2002 -- Continued olanzapine treatment appears to significantly delay symptomatic relapse in patients with bipolar disorder who are stabilized with olanzapine and lithium or with valproate, researchers reported at the annual meeting of the American Psychiatric Association (APA).

        "For patients, each day spent with manic or depressive symptoms can be devastating," said lead researcher Mauricio F. Tohen, MD, of the department of research, Eli Lilly and Company in Indianapolis. "So maintaining remission over time is vital."

        After six weeks of acute therapy, subjects who reached a remission of symptoms on olanzapine combined with lithium or valproate were randomized to olanzapine 5-20 mg/day (30 patients) or placebo (38 patients), concomitant with ongoing valproate (50-125 mg/mL) or lithium (0.6-1.2 mEq/L). Remission was defined as a score of 12 or less on the Young Mania Rating Scale and a score of 8 or less on the Hamilton Depression Rating Scale.

        Placebo subjects in remission from symptoms of bipolar disorder at the end of the acute therapy relapsed into mania or depression at a rate of 55.3 percent during the 18-month trial, while olanzapine-treated patients relapsed at a rate of 36.7 percent (p=0.149).

        Time to bipolar relapse differed markedly (p=0.023) between the two groups. Twenty-five percent of placebo-treated patients relapsed into mania or depression by day 15; 25 percent of olanzapine-treated patients relapsed into mania or depression by day 124. The researchers noted relapse to mania in 28.9 percent of placebo-treated patients and in 20.0 percent of olanzapine-treated patients (p=0.574). Rates of relapse to depression were 39.5 percent for the placebo group and 23.3 for the olanzapine group (p=0.197).

        "Often a mood stabilizer is not enough to adequately control all phases of the illness and maintain remission, so doctors may need to consider appropriate additional medication to stabilize mood," said Paul Keck, MD, professor of medicine at the University of Cincinnati College of Medicine. "These data suggest that olanzapine, when added to lithium or valproate, may help improve the long-term picture."

        Funding for this study was provided by Eli Lilly and Company.



        E-Mail this DGDispatch to a colleague   To print, use this version






        All contents Copyright (c) 1995-2008 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send